CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 139 enrolled
Drug / intervention
PvP001 100 mg +11 moredrug
Likely dose
PvP001 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03701555
NCT03701555Phase 1Completed

A Phase 1, Four-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Gluten Degradation Activity of PvP001, PvP002, and PvP003 in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and Pharmacokinetics of PvP001 and PvP002 in Adults With Celiac Disease

Millennium Pharmaceuticals, Inc.·interventional·Posted Oct 10, 2018·Updated Apr 4, 2023

In Brief

A Phase 1 clinical trial evaluating PvP001 placebo, PvP001 100 mg, and 10 other interventions for Digestive System Disease. Completed, enrolled 139 participants across 1 site.

Detailed Summary

It is hoped that different forms of the same medicine, called PVP001, PVP002, and PVP003, will help people with celiac disease. Both healthy adults and adults with celiac disease will take part in this study. There are many main aims of the study. * To check if participants have side effects from different forms of the study medicine. These forms are called PVP001 (liquid in a cup), PVP002 capsule, and PVP003 tablet. * To check how well PVP003 breaks down gluten. * To check how much PVP003 participants can take without getting side effects from it. The study is in 4 parts. At the start of each part of the study, the study doctor will check to determine who can take part at the first study visit. Different groups of participants will be in different parts of the study. In all parts of the study, some participants will take 1 of the 3 forms of study medicine. Others will take a placebo. In this study, a placebo will look like the form of study medicine but will not have any medicine in it. This means that a placebo can either look like PVP001 liquid in a cup, the PVP002 tablet, or the PVP003 tablet. In Part 1, different small groups of participants will take lower to higher doses of PVP001 or PVP002 or a placebo. This is to work out the best dose of study medicine to take in other parts of the study. After treatment, participants will regularly visit the clinic to check that they have no problems with their treatment, including any side effects from their treatment. In Part 2, different small groups will take different doses of PVP001 or PVP002 or a placebo, either with or without a meal that has different amounts of gluten in it. This is to check if PVP001 or PVP002 has broken down gluten in the body. Participants will visit the clinic after treatment to check how much gluten has been broken down in the body. In Part 3, different small groups will take different doses of PVP003 or a placebo, either with or without a meal that has gluten in it. This is to check if PVP003 has broken down gluten in the body. Participants will visit the clinic after treatment to check if more gluten has broken down in the body. In Part 4, different small groups will take PVP003 or placebo 3 times a day for 5 days. After treatment, participants will visit the clinic to check that they have no problems with their treatment, including any side effects from their treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 10, 2018
Enrollment StartJun 19, 2018
Primary CompletionJan 31, 2021
Study CompletionJul 2, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.7 years ago

Interventions

PvP001 placeboother

placebo

PvP001 100 mgdrug

PvP001 100 mg

PvP001 300 mgdrug

PvP001 300 mg

PvP001 900 mgdrug

PvP001 900 mg

Maximum Feasible Dose (MFD) of PvP002drug

MFD of PvP002

Maximum Tolerated Dose (MTD) of PvP001drug

Maximum Tolerated Dose (MTD) of PvP001

MTD of PvP001 following 7 days of PPI treatmentdrug

Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment

PvP002 placeboother

Placebo

PvP001 600 mgdrug

PvP001 600 mg

PvP003 placebodrug

Placebo tablet orally.

PvP003drug

PvP003 tablet orally.

PvP003 150 mgdrug

PvP003 150 mg